AJP - Renal Journal of Applied Physiology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Am J Physiol Renal Physiol 293: F1083-F1092, 2007. First published June 27, 2007; doi:10.1152/ajprenal.00401.2006
0363-6127/07 $8.00
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
293/4/F1083    most recent
00401.2006v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (11)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Allard, J.
Right arrow Articles by Girolami, J.-P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Allard, J.
Right arrow Articles by Girolami, J.-P.

ACE inhibitor reduces growth factor receptor expression and signaling but also albuminuria through B2-kinin glomerular receptor activation in diabetic rats

Julien Allard,1 Marie Buléon,1 Eric Cellier,1 Isabelle Renaud,2 Christiane Pecher,1 Françoise Praddaude,1 Marc Conti,2 Ivan Tack,1 and Jean-Pierre Girolami1

1Institut National de la Santé et de la Recherche Médicale U858 eq 5 and Physiology Department, Louis Bugnard Institute, Toulouse Cedex 4; and 2Laboratoire de Biochimie 1, CHU de Bicêtre, Le Kremlin-Bicêtre, France

Submitted 11 October 2006 ; accepted in final form 24 June 2007

Diabetic nephropathy (DN) is associated with increased oxidative stress, overexpression and activation of growth factor receptors, including those for transforming growth factor-beta1 (TGF-beta-RII), platelet-derived growth factor (PDGF-R), and insulin-like growth factor (IGF1-R). These pathways are believed to represent pathophysiological determinants of DN. Beyond perfect glycemic control, angiotensin-converting enzyme inhibitors (ACEI) are the most efficient treatment to delay glomerulosclerosis. Since their mechanisms of action remain uncertain, we investigated the effect of ACEI on the glomerular expression of these growth factor pathways in a model of streptozotocin-induced diabetes in rats. The early phase of diabetes was found to be associated with an increase in glomerular expression of IGF1-R, PDGF-R, and TGF-beta-RII and activation of IRS1, Erk 1/2, and Smad 2/3. These changes were significantly reduced by ACEI treatment. Furthermore, ACEI stimulated glutathione peroxidase activity, suggesting a protective role against oxidative stress. ACEI decreased ANG II production but also increased bradykinin bioavailability by reducing its degradation. Thus the involvement of the bradykinin pathway was investigated using coadministration of HOE-140, a highly specific nonpeptidic B2-kinin receptor antagonist. Almost all the previously described effects of ACEI were abolished by HOE-140, as was the increase in glutathione peroxidase activity. Moreover, the well-established ability of ACEI to reduce albuminuria was also prevented by HOE-140. Taken together, these data demonstrate that, in the early phase of diabetes, ACEI reverse glomerular overexpression and activation of some critical growth factor pathways and increase protection against oxidative stress and that these effects involve B2-kinin receptor activation.

angiotensin-converting enzyme inhibitor; oxidative stress; glutathione peroxidase activity; diabetes



Address for reprint requests and other correspondence: J. P. Girolami, Institut National de la Santé et de la Recherche Médicale U388 Louis Bugnard Institute, BP 84225, 31432 Toulouse Cedex 4, France (e-mail: girolami{at}toulouse.inserm.fr)




This article has been cited by other articles:


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
N. Engberding, A. San Martin, A. Martin-Garrido, M. Koga, L. Pounkova, E. Lyons, B. Lassegue, and K. K. Griendling
Insulin-Like Growth Factor-1 Receptor Expression Masks the Antiinflammatory and Glucose Uptake Capacity of Insulin in Vascular Smooth Muscle Cells
Arterioscler. Thromb. Vasc. Biol., March 1, 2009; 29(3): 408 - 415.
[Abstract] [Full Text] [PDF]


Home page
Journal of Renin-Angiotensin-Aldosterone SystemHome page
P. Vieitez, O. Gomez, E. R Uceda, M. E. Vera, and E. Molina-Holgado
Systemic and local effects of angiotensin II blockade in experimental diabetic nephropathy
Journal of Renin-Angiotensin-Aldosterone System, June 1, 2008; 9(2): 96 - 102.
[Abstract] [PDF]


Home page
DiabetesHome page
Y. Qian, E. Feldman, S. Pennathur, M. Kretzler, and F. C. Brosius III
From Fibrosis to Sclerosis: Mechanisms of Glomerulosclerosis in Diabetic Nephropathy
Diabetes, June 1, 2008; 57(6): 1439 - 1445.
[Full Text] [PDF]


Home page
Am. J. Physiol. Renal Physiol.Home page
M. Buleon, J. Allard, A. Jaafar, F. Praddaude, Z. Dickson, M.-T. Ranera, C. Pecher, J.-P. Girolami, and I. Tack
Pharmacological blockade of B2-kinin receptor reduces renal protective effect of angiotensin-converting enzyme inhibition in db/db mice model
Am J Physiol Renal Physiol, May 1, 2008; 294(5): F1249 - F1256.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2007 by the American Physiological Society.